Bibliography
- Wigley FM. Clinical practice. Raynaud's Phenomenon. N Engl J Med 2002;347(13):1001-8
- Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ 1990;301:590-2
- Wigley FM. Raynaud's phenomenon. Curr Opin Rheumatol 1993;5:773-84
- Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud's Phenomenon: a 5 region comparison. J Rheumatol 1997;24:879-89
- Watson HR, Robb R, Belcher G, Belch JJ. Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 1999;26:1734-7
- Planchon B, Pistorius MA, Beurrier P, De Faucal P. Primary Raynaud's phenomenon: age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994;45:677-86
- Le Roy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992;10:485-8
- Kallenberg CG. Early detection of connective tissue disease in patients with Raynaud's phenomenon. Rheum Dis Clin North Am 1990;16:11-30
- Kallenberg CG, Wouda AA, Hoet MH, Van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon : a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988;47:634-41
- Kahaleh MB, Le Roy EC. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 1999;31:195-214
- Matucci Cerinic M, Kahaleh BM, LeRoy EC. The vascular inVolumeement in systemic sclerosis. In: Furst D, Clements P, editors, Systemic sclerosis. Baltimore: Lea & Febiger; 1995. p. 153-74
- Matucci Cerinic M, Generini S, Pignone A. New approaches to Raynaud's phenomenon. Curr Opin Rheumatol 1997;9:544-51
- Kahaleh BM. Endothelin: an endothelial dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83
- Rustin MHA, Bull HA, Machin SJ, et al. Serum from patients with Raynaud's phenomenon inhibits prostacyclin production. J Invest Dermatol 1987;89:555-9
- Kahaleh BM, Pan-Sheng F, Cerinic MM, et al. Study of endothelial dependent relaxation in scleroderma. Arthritis Rheum 1993;(36 Suppl):B233
- Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990;30:535-60
- Cerinic MM, Kahaleh MB. Beauty and the Beast: the nitric oxide paradox in systemic sclerosis. Rheumatology 2002;41:843-7
- Freedman RR, Girgis R, Mayes M. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. J Rheumatol 1999;26:2386-8
- Herrick AL, Cerinic MM. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001;19:1-3
- Rubanyi GM, Ho EH, Cantor EH, et al. Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes. Biochem Biophys Res Commun 1991;181:1392-7
- O'Donnell VB, Freeman BA. Interactions between nitric oxide and lipid oxidation pathway: implications for vascular disease. Circ Res 2001;88:12-21
- Cerinic MM, Generini S, Pignone A, Cagnoni M. From Raynaud's phenomenon to systemic sclerosis: lack or exhaustion of adaptation? Adv Org Biol 1998;6:241-52
- Sgonc R, Grushwitz MS, Boeck G, et al. Endothelial cell apoptosis in systemic sclerosis induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000;43:2550-62
- Foresti R, Sarathchandra P, Clark JE, et al. Peroxynitrite induces haem-1 oxygenase-1 in vascular endothelial cells: a link to apoptosis. Biochem J 1999;339:729-36
- Shen YH, Wang XL, Wilcken DE. Nitric oxide induces and inhibits apoptosis through different pathways. FEBS 1998;433:125-31
- Physician' Desk Reference 2007. Thomson PDR, Montvale NJ 07645, USA
- Watanabe H. Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension. Intern Med 2004;43(10):891-3
- Friedman GA, Harris PA, Wood AJ, et al. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. Clin Pharmacol Ther 2007;82(4):503-9
- Baumhaekel M, Scheffler P, Boehm M. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvasc Res 2005;69(3):178-9
- Baak SW. Treatment of Raynaud's phenomena with PDE-5 inhibitor, cialis (tadalafil) in patients with scleroderma and lupus. Arthritis Rheum 2005;52(Suppl 9):S169
- Cheung GTY, Lau CS, Kumana CR. Phosphodiesterase 5-inhibitors relieve symptoms of severe Raynaud's phenomenon. Ann Rheum Dis 2004;64 (Suppl 2):211
- Colglazier CL, Sutej PG, O'Rourke KS. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J Rheumatol 2005;32(12):2440-2
- Gore J, Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005;64:1387
- Kamata Y, Kamimura T, Iwamoto M, Minota S. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis. Clin Exp Dermatol 2005;30:435-56
- Kropman RF. Raynaud's phenomenon of the penis. J Urol 2004;171(4):1630
- Lichtenstein JR. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al. Arthritis Rheum 2003;48(1):282-3
- Rosenkranz S, Caglayan E, Diet F, et al. Long- term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome. Dtsch Med Wochenschr 2004;129(33):1736-40
- Yung A, Reay N, Goodfield MD. Improvement in digital flexibility and dexterity following ingestion of sildenafil citrate (Viagra) in limited systemic sclerosis. Arch Dermatol 2005;141:831-3
- Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006;166:231-3
- Carlino G. Treatment of Raynaud's phenomenon with tadalafil, a phosphodiesterase-5 inhibitor. Ann Rheum Dis 2005;64(Suppl 3):258
- Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5
- Kumar N, Griffiths B, Allen J. Thermographic and symptomatic effects of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment. J Rheumatol 2006;33(9):1918-9
- Sandorfi N, Jimenez SA. Treatment of digital ulceration due to Raynaud's phenomenon (RP) with long acting phosphodiesterase 5 (PDE5) inhibitor: tadalafil. Ann Rheum Dis 2007;66(Suppl 2):223
- Zamiri B, Koman AL, Smith BP, et al. Double-blind, placebo-controlled trial of sildenafil for the management of primary Raynaud's phenomenon. Ann Rheum Dis 2004;63 (Suppl 2):342
- Schiopu E, Hsu VM, Impens AJ, et al. Controlled trial of tadalafil in Raynaud's phenomenon (RP) secondary to systemic sclerosis. Arthritis Rheum 2006;54(Suppl):505
- Pakozdi A, Howell K, Black CM, Denton CP. Addition of the short term phosphodiesterase-5 inhibitor sildenafil to iloprost therapy for scleroderma digital vasculopathy. Arthritis Rheum 2007;56(Suppl):825